Rain Oncology Inc. Common Stock

RAIN

Market cap $44M

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rain Oncology Inc. (NasdaqGS: RAIN) to Pathos AI, Inc. Under the terms of the proposed transaction, shareholders of Rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of Rain that they own. KSF is seeking to deter.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rain Oncology Inc. (NasdaqGS: RAIN) to Pathos AI, Inc. Under the terms of the proposed transaction, shareholders of Rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of Rain that they own. KSF is seeking to deter.

MILWAUKEE , Dec. 14, 2023 /PRNewswire/ -- Ademi LLP is investigating Rain (NASDAQ: RAIN) for possible breaches of fiduciary duty and other violations of law in its transaction with Pathos. Click here to learn how to join the https://www.ademilaw.com/case/rain-oncology-inc or call Guri Ademi toll-free at 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Rain Oncology Inc. (NASDAQ: RAIN) to Pathos AI, Inc. for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share is fair to Rain shareholders. Halper Sadeh encourages Rain shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060.

NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to approximately $0.17 per share.